*Joint last authors; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf; Department of Pediatrics, University Medical Center Hamburg-Eppendorf; Institute of Human Genetics, Klinikum Rechts der Isar, TUM, Munich; Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen; Institute of Human Genetics, Helmholtz Center Munich; Undiagnosed Disease Program at the University Medical Center Hamburg-Eppendorf (UDP-UKE).
Dtsch Arztebl Int. 2019 Mar 22;116(12):197-204. doi: 10.3238/arztebl.2019.0197.
In developed countries, global developmental disorders are encounter- ed in approximately 1% of all children. The causes are manifold, and no exogenous cause can be identified in about half of the affected children. The parallel investi- gation of the coding sequences of all genes of the affected individual (whole exome sequencing, WES) has developed into a successful diagnostic method for identify- ing the cause of the problem. It is not yet clear, however, when WES should best be used in routine clinical practice in order to exploit the potential of this method to the fullest.
In an interdisciplinary study, we carried out standardized clinical pheno- typing and a systematic genetic analysis (WES of the index patient and his or her parents, so-called trio WES) in 50 children with developmental disturbances of unclear etiology and with nonspecific neurological manifestations.
In 21 children (42% of the collective), we were able to identify the cause of the disorder by demonstrating a mutation in a gene known to be associated with disease. Three of these children subsequently underwent specific treatment. In 22 other children (44%), we detected possibly etiological changes in candidate genes not currently known to be associated with human disease.
Our detection rate of at least 42% is high in comparison with the results obtained in other studies from Germany and other countries to date and implies that WES can be used to good effect as a differential diagnostic tool in pediatric neurol- ogy. WES should be carried out in both the index patient and his or her parents (trio- WES) and accompanied by close interdisciplinary collaboration of human geneti- cists and pediatricians, by comprehensive and targeted phenotyping (also after the diagnosis is established), and by the meticulous evaluation of all gene variants.
在发达国家,所有儿童中约有 1%患有全球发育障碍。病因多种多样,大约一半受影响的儿童无法确定外源性病因。对受影响个体的所有基因编码序列(外显子组测序,WES)进行平行研究已经成为识别问题原因的一种成功诊断方法。然而,目前尚不清楚在常规临床实践中何时最好使用 WES,以便充分利用这种方法的潜力。
在一项跨学科研究中,我们对 50 名病因不明且具有非特异性神经表现的发育障碍儿童进行了标准化临床表型和系统遗传分析(先证者及其父母的 WES,即所谓的 trio WES)。
在 21 名儿童(42%的群体)中,我们通过证明与疾病相关的基因中的突变来确定疾病的原因。其中 3 名儿童随后接受了特定治疗。在另外 22 名儿童(44%)中,我们检测到候选基因中可能与病因相关的变化,这些基因目前尚未被认为与人类疾病有关。
与迄今为止德国和其他国家的其他研究结果相比,我们的检测率至少为 42%,这表明 WES 可以作为儿科神经学的一种有效的鉴别诊断工具。WES 应在先证者及其父母(trio-WES)中进行,并由人类遗传学家和儿科医生密切的跨学科合作、全面和有针对性的表型分析(即使在诊断确定后)以及对所有基因变异的细致评估来辅助。